((自动化翻译由路透提供，请见免责声明 ))
10月14日 - ** 药物开发商Longboard Pharmaceuticals 股价盘前上涨49.4%至58.10美元
** 丹麦 H Lundbeck A/S 表示，它将以 26 亿美元的价格收购 (link) Longboard，以扩大其治疗神经罕见疾病的产品线。
** 灵北将以每股 60 美元的价格收购 Longboard 的全部股份，与该股上次收盘价 38.90 美元相比溢价 54.2
** LBPH公司的主要候选药物bexicaserin正处于后期开发阶段，用于治疗与一组癫痫相关的癫痫发作。
** 截至上次收盘，该公司股价年累计涨幅超过六倍
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.